TABLE 3.
Overview of Studies Comparing Performance of 99mTc-Sestamibi with Pathology
| 99mTc-sestamibi compared with pathology | ||||||
|---|---|---|---|---|---|---|
| First author | Year | Patients with pathology | TP | FP | TN | FN |
| Amadou | 2019 | 23 | 9 | 1 | 0 | 13 |
| Bossert | 2019 | 17 | 3 | 0 | 0 | 14 |
| Huber | 2018 | 26 | 2 | 0 | 0 | 24 |
| Khafif | 2019 | 19 | 17 | 0 | 0 | 2 |
| Kluijfhout | 2017 | 33 | 8 | 0 | 0 | 21 |
| Lezaic | 2014 | 24 | 14 | 0 | 0 | 10 |
| Michaud | 2014 | 12 | 8 | 2 | 0 | 2 |
| Thanseer | 2017 | 54 | 42 | 1 | 1 | 10 |
| Uslu-Beşli | 2020 | 80 | 39 | 1 | NA | NA |
| Zajíčková | 2018 | 13 | 4 | 2 | 0 | 7 |
| Total | 301 | 146 | 7 | 1 | 103 | |
TP = true positive; FP = false positive; TN = true negative; FN = false negative; NA = not applicable.